Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 9/20 | 0.60 |
| ▸ | GRM5 | P41594 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | UGCG | Q16739 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2021271 | 1.00 | GHSR (0.60) | GHSRGRM5POLBGFERMAPK1 | |
| SCHEMBL15084148 | 0.89 | GRM5 (0.50) | GHSRGRM5POLBGFERMAPK1 | |
| SCHEMBL15081820 | 0.88 | GRM5 (0.49) | GHSRGRM5POLBGFERMAPK1 | |
| SCHEMBL15081817 | 0.85 | GRM5 (0.55) | GHSRGRM5POLBGFERMAPK1 | |
| SCHEMBL4334106 | 0.84 | GRM5 (0.54) | GRM5POLBGFERMAPK1UGCG | |
| SCHEMBL6161700 | 0.84 | GHSR (0.58) | GHSRTACR1 | |
| SCHEMBL6161692 | 0.84 | GHSR (0.58) | GHSRTACR1 | |
| SCHEMBL15084146 | 0.84 | GRM5 (0.58) | GRM5POLBGFERMAPK1UGCG | |
| Hydrochloric Acid SCHEMBL6160711 | 0.83 | GHSR (0.57) | GHSRTACR1 | |
| Hydrochloric Acid SCHEMBL6160707 | 0.83 | GHSR (0.57) | GHSRTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883721-B2 | Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof | MCGILL UNIVERSITY (CA) | 2014-11-11 | — | — | US | claimed |
| US-20120135918-A1 | METHODS OF INHIBITING THE GHRELIN/GROWTH HORMONE SECRETATOGUE RECEPTOR PATHWAY AND USES THEREOF | MCGILL UNIVERSITY (CA) | 2012-05-31 | — | — | US | claimed |
| US-20090069245-A1 | GHRELIN/GROWTH HORMONE RELEASING PEPTIDE/GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2009-03-12 | — | — | US | claimed |
| US-10550377-B2 | Suppression of prostate cancer using a targeted clostridial neurotoxin | IPSEN BIOINNOVATION LIMITED (GB) | 2020-02-04 | — | — | US | disclosed |
| EP-2719392-B1 | Fusion proteins for use in the treatment of acromegaly | IPSEN BIOINNOVATION LTD (GB) | 2019-07-24 | — | — | EP | disclosed |
| US-20190127718-A1 | SUPPRESSION OF CANCER | IPSEN BIOINNOVATION LIMITED (GB) | 2019-05-02 | — | — | US | disclosed |
| EP-3473643-A1 | FUSION PROTEINS FOR USE IN THE TREATEMNT OF CANCER | Ipsen Bioinnovation Limited (GB) | 2019-04-24 | — | — | EP | disclosed |
| EP-2310029-B1 | Fusion proteins for use in the treatment of cancer | IPSEN BIOINNOVATION LTD (GB) | 2019-04-03 | — | — | EP | disclosed |
| US-10240138-B2 | Polypeptides that bind to and inhibit secretion from growth hormone secreting cells | IPSEN BIOINNOVATION LIMITED | 2019-03-26 | — | — | US | disclosed |
| US-10113159-B2 | Suppression of cancer | IPSEN BIOINNOVATION LIMITED (GB) | 2018-10-30 | — | — | US | disclosed |
| EP-3241560-A1 | SUPPRESSION OF CANCER | Ipsen Bioinnovation Limited (GB) | 2017-11-08 | — | — | EP | disclosed |
| US-20120135918-A1 | METHODS OF INHIBITING THE GHRELIN/GROWTH HORMONE SECRETATOGUE RECEPTOR PATHWAY AND USES THEREOF | MCGILL UNIVERSITY (CA) | 2012-05-31 | — | — | US | disclosed |
| US-20110165137-A1 | SUPPRESSION OF CANCERS | SYNTAXIN LIMITED (GB) | 2011-07-07 | — | — | US | disclosed |
| US-20110160135-A1 | SUPPRESSION OF NEUROENDOCRINE DISEASES | SYNTAXIN LIMITED (GB) | 2011-06-30 | — | — | US | disclosed |
| US-20110158973-A1 | SUPPRESSION OF CANCERS | SYNTAXIN LIMITED (GB) | 2011-06-30 | — | — | US | disclosed |
| WO-2010132580-A2 | METHODS OF INHIBITING THE GHRELIN/GROWTH HORMONE SECRETATOGUE RECEPTOR PATHWAY AND USES THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2010-11-18 | — | — | WO | disclosed |
| US-20090069245-A1 | GHRELIN/GROWTH HORMONE RELEASING PEPTIDE/GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2009-03-12 | — | — | US | disclosed |
| EP-2021015-A2 | GHRELIN/GROWTH HORMONE RELEASING PEPTIDE/GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | The Administrators Of The Tulane Educational Fund (US) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007127457-A9 | GHRELIN/GROWTH HORMONE RELEASING PEPTIDE/GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | UNIV TULANE (US) | 2008-04-03 | — | — | WO | disclosed |
| WO-2007127457-A2 | GHRELIN/GROWTH HORMONE RELEASING PEPTIDE/GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135918-A1 | METHODS OF INHIBITING THE GHRELIN/GROWTH HORMONE SECRETATOGUE RECEPTOR PATHWAY AND USES THEREOF | GHSR, GIPR, GHRHR | GHSR 1/4885GRM5 396/4885POLB 4820/4885 |
| US-20090069245-A1 | GHRELIN/GROWTH HORMONE RELEASING PEPTIDE/GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | GHSR, GHRHR, GIPR | GHSR 1/4885GRM5 186/4885POLB 3917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.